Evaluation of the potential herb-drug interaction between Bojungikki-tang and PD-L1 immunotherapy in a syngeneic mouse model
Atezolizumab (a PD-L1 inhibitor) has shown remarkable efficacy and tolerability in various cancer types.Despite its efficacy and safety, atezolizumab monotherapy has limitations, such as acquired resistance and adverse events.Bojungikki-tang (BJIKT) is an herbal decoction widely prescribed in Asian countries and used to treat cancer-related symptom